Integrated Diagnosis and Treatment of Adults With Attention-deficit/Hyperactivity Disorder
Completed
- Conditions
- Adult Attention-deficit/Hyperactivity Disorder
- Registration Number
- NCT01615679
- Lead Sponsor
- Medice Arzneimittel Pütter GmbH & Co KG
- Brief Summary
Non-interventional study to gain further information about the therapy progression in routine treatment of adults with attention-deficit/hyperactivity disorder (ADHD). Main focus will be on the improvement of the clinical global impression (CGI) in comparison to the outcome of randomized, controlled studies.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 468
Inclusion Criteria
- Adult patients with newly diagnosed ADHD
Exclusion Criteria
- Known sensitivity to methylphenidate or any of the excipients
- Glaucoma
- Phaeochromocytoma
- During treatment with non-selective, irreversible monoamine oxidase (MAO) inhibitors, or within a minimum of 14 days of discontinuing those drugs, due to risk of hypertensive crisis
- Hyperthyroidism or Thyrotoxicosis
- Diagnosis or history of severe depression, anorexia nervosa/anorexic disorders, suicidal tendencies, psychotic symptoms, severe mood disorders, mania, schizophrenia, psychopathic/borderline personality disorder.
- Diagnosis or history of severe and episodic (Type I) Bipolar (affective) Disorder (that is not well-controlled)
- pre-existing cardiovascular disorders including severe hypertension, heart failure, arterial occlusive disease, angina, haemodynamically significant congenital heart disease, cardiomyopathies, myocardial infarction, potentially life-threatening arrhythmias and channelopathies (disorders caused by the dysfunction of ion channels)
- pre-existing cerebrovascular disorders cerebral aneurysm, vascular abnormalities including vasculitis or stroke
- a history of pronounced anacidity of the stomach with a pH value above 5.5, in therapy with H2-receptor blockers or in antacid therapy,
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinical Global Impression (CGI) 12-14 weeks
- Secondary Outcome Measures
Name Time Method Wender-Reimherr adult attention deficit disorder scale (WRAADDS) - self-report 12-14 weeks
Trial Locations
- Locations (1)
Universität des Saarlandes, Gerichtliche Psychologie und Psychiatrie
🇩🇪Homburg, Germany